Attaya Suvannasankha is an Oncology physician affiliated with Indiana University Health. OpenAlex indexes 226 publications with 4,015 citations (h-index 30); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1044 W Walnut St
R4 202
Indianapolis, IN 462025254
Telephone
317-274-0843Provider last certified this registry record 12 Mar 2025.
Clinical trials
- Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Sponsor: Attaya Suvannasankha
- Role of Osteocytes in Myeloma Bone Disease
Sponsor: Attaya Suvannasankha
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$16,995openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20255 payments
- Janssen Biotech, Inc.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Preclinical Validation of Adjuvant Fingolimod to Increase Efficacy of Proteasome Inhibitors for Treatment of Multiple Myeloma
Rlr Va Medical Center
FY2026I01CX000623 - Preclinical Validation of Adjuvant Fingolimod to Increase Efficacy of Proteasome Inhibitors for Treatment of Multiple Myeloma
Rlr Va Medical Center
FY2024I01CX000623 - A Novel Agent to Suppress Tumor Growth in Bone, Prevent Cachectic Muscle Loss and Preserve Skeletal Integrity
Rlr Va Medical Center
FY2022I01BX004514
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Zipes, MD
Indiana University Health
Lawrence Einhorn, MD
Indiana University Health
Lisa Landrum, MD
Indiana University Health
Patrick Loehrer, MD
Indiana University Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”